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Abstract
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) began harmonizing clinical breakpoints in Europe 2002. In
2009, work to develop a disc diffusion method began and the ﬁrst disc diffusion breakpoints calibrated to EUCAST clinical MIC breakpoints
were published in December 2009. In this study we validated EUCAST clinical zone diameter breakpoints against the International Standard
Organization (ISO) reference broth microdilution. A collection of 544 isolates (238 Gram-negative and 306 Gram-positive) were tested
against a panel of antimicrobial agents. Antimicrobial susceptibility testing was performed with broth microdilution as described by ISO and
disc diffusion in accordance with EUCAST methodology. Inhibition zone diameters and MIC values were interpreted and categorized (S, I
and R) according to EUCAST clinical breakpoint table version 2.0. Categorical agreement (CA) as well as minor (mD), major (MD) and very
major (VMD) discrepancies were determined. There was in general good correlation between susceptibility test results obtained with disc
diffusion and broth microdilution. Overall CA was 97.3% for all combinations of organisms and antimicrobial agents (n = 5231) and the
overall discrepancy rates were 110 (2.1%) mD, 24 (0.5%) MD and 7 (0.1%) VMD. The overall CA for Gram-positive and Gram-negative
organisms were 98.7% (2346 tests) and 96.2% (2942 tests), respectively. Seven VMD were observed, ﬁve for Gram-positive organisms
(coagulase negative staphylococci (n = 2) and Staphylococcus aureus (n = 3)) and two for Gram-negative organisms (Pseudomonas aeruginosa).
Minor discrepancies were mainly observed in Gram-negatives and were related to different antimicrobial agents and species.
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Introduction
Between 2002 and 2010, the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) harmonized
the clinical breakpoints for antimicrobial agents commonly
used in Europe [1]. During this process, EUCAST decided in
2009 to develop a standardized European disc diffusion
susceptibility test method based on the Kirby–Bauer proce-
dure, Mueller–Hinton agar and a 0.5 McFarland inoculum.
Mueller–Hinton agar without supplements is used for non-fas-
tidious bacteria and Mueller–Hinton agar with 5% mechanically
deﬁbrinated horse blood and 20 mg/L b-NAD is used for
fastidious bacteria such as streptococci (including Streptococcus
pneumoniae), Haemophilus inﬂuenzae, Moraxella catarrhalis,
Pasteurella multocida, Campylobacter spp. and several more.
The disc diffusion method is calibrated against EUCAST MIC
breakpoints as described in a recent article on the EUCAST
disc diffusion method and as shown for many combinations of
agents and species on the EUCAST website [2,3] The clinical
breakpoints tables, recommendations on methodology and
quality assurance are published on the EUCAST website
[www.eucast.org]. A survey performed by EUCAST in early
2012 and data from the National External Quality Assessment
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Service (NEQAS) and the European Antimicrobial Resistance
Surveillance Network (EARS-Net) indicate that almost all
European countries are now in the process of implementing
EUCAST breakpoints and in most instances also the EUCAST
disc diffusion test (personal communication, Christine Walton,
UKNEQAS).
Broth microdilution, as described by the International
Standards Organization (ISO), is the international reference
method for MIC determination in non-fastidious organisms [4].
ISO has also established criteria for comparing categorical
antimicrobial susceptibility testing results with reference
methodology [5]. The aim of this study was to evaluate the
EUCAST disc diffusion method versus broth microdilution by
using EUCAST clinical breakpoints [6] and established ISO
documents [4,5].
Materials and Methods
Bacterial isolates
A collection of 544 clinical isolates, including 238 Gram-neg-
ative and 306 Gram-positive organisms, were collected during
1994–2011 (Table 1). Species identiﬁcation was performed with
standard biochemical methods. Some isolates were selected
because of speciﬁc resistance mechanisms (methicillin-resistant
Staphylococcus aureus (MRSA), extended spectrum b-lactamase-
producing Enterobacteriaceae (ESBL) and vancomycin-resistant
enterococci) and resistance mechanisms were conﬁrmed using
genotypic methods. The following quality control reference
strains were included: Enterococcus faecalis ATCC 29212,
Streptococcus pneumoniae ATCC 49619, S. aureus ATCC
29213, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853. As positive control for MRSA and ESBL
detection, S. aureus ATCC 43300 and Klebsiella pneumoniae
ATCC 700603 were used, respectively.
Antimicrobial susceptibility testing
The isolates were subcultured twice using blood agar plates
(Oxoid, Thermo Fisher Scientiﬁc, Basingstoke, UK) and
incubated overnight at 35°C, in ambient air for non-fastidious
organisms and in 5% CO2 for fastidious organisms. A bacterial
suspension was made in Sensititre demineralized water
equivalent to a 0.5 McFarland standard by using a Sensititre
nephelometer (TREK, Thermo Fisher Scientiﬁc). The same
suspension was used for disc diffusion testing and broth
microdilution. The isolates were evaluated against a panel of
antimicrobial agents (Table 2) relevant to the EUCAST
breakpoint table v. 2.0 published on 1 January 2012 [6].
Broth microdilution method
Custom freeze-dried broth microdilution plates for non-
fastidious Gram-negative and Gram-positive bacteria (Sensititre,
TREK Diagnostic System, Cleveland, OH, USA) were manufac-
tured for this study. The MIC ranges were adjusted to ﬁt
EUCAST MIC breakpoints (Table 2). For streptococci we used a
standard Sensititre plate, STP6F, and to detect inducible
clindamycin resistance in staphylococci we used plate GPALL1F.
All plates were delivered with a quality control certiﬁcate
showing that MICs of pertinent control strains were within
CLSI- and/or EUCAST-deﬁned ranges.
For each plate type, broth microdilution was carried out
according to the recommendations of the manufacturer.
Cation-adjusted Mueller–Hinton broth with N-Tris (Hydro-
xymethyl)methyl-2-Amino-Ethanesulfonic Acid (TES-buffer)
(CAMHBT) was used for non-fastidious bacteria and CAMHB
with 2.5% lysed horse blood (CAMHBT + LHB) was used for
fastidious bacteria. We obtained documentation from TREK to
show that all materials were approved by the US Food and
Drug Administration and that the TES buffer increases the pH
stability of the broth without inﬂuencing the MIC determina-
tion. The plates were inoculated by using Sensititre AIMTM
(TREK, Thermo Fisher Scientiﬁc). Non-fastidious organisms
were incubated at 35°C for 18 h. Plates for detection of
inducible clindamycin resistance and resistance to vancomycin
in enterococci were incubated for 24 h. Fastidious organisms
were incubated at 35°C for 20–24 h. All plates were read
manually using the Sensititre Vizion system and Sensititre
Windows Software SWIN (TREK, Thermo Fisher Scientiﬁc,
Basingstoke, UK).
TABLE 1. Species and deﬁned resistance mechanisms
Organism No. tested
Gram-positive organisms (n = 306)
Staphylococcus aureus 94
…of which mecA positivea 30
Coagulase-negative staphylococci 28
Staphylococcus lugdunensis 9
Enterococcus faecalis 41
… of which with HLAR 16
…of which VREb 5
Enterococcus faecium 57
… of which with HLAR 16
… of which VREb 21
Streptococcus pneumoniae 35
Streptococcus pyogenes 42
Gram-negative organisms (n = 238)
Escherichia coli 87
…of which with ESBLc 26
Klebsiella pneumoniae 50
…of which with ESBLc 8
Klebsiella oxytoca 12
Morganella morganii 10
Proteus mirabilis 22
Enterobacter aerogenes 9
Enterobacter cloacae 13
Pseudomonas aeruginosa 35
ESBL, extended spectrum b-lactamase producing Enterobacteriaceae; HLAR, high
level aminoglycoside resistance; VRE, vancomycin-resistant enterococci.
aVarious spa types.
bvanA and vanB.
cCTX-M 1, 9, 14, 15.
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Disc diffusion test
Disc diffusion testing was performed in accordance with
EUCAST recommendations [2]. For susceptibility testing,
plates with Mueller–Hinton agar (Oxoid,Thermo Fisher Sci-
entiﬁc, Basingstoke, UK and Becton Dickinson, Franklin Lakes,
NJ, USA) without supplements were used for non-fastidious
organisms and with 5% horse blood and 20 mg/L b-NAD for
streptococci. Antimicrobial discs were obtained from Oxoid
(Thermo Fisher Scientiﬁc).
Data analysis
The antimicrobial susceptibility testing results, MIC values and
zone diameters, were categorized as susceptible (S), interme-
diate (I) or resistant (R) using EUCAST clinical breakpoint table
version 2.0, January 2012 [6]. Categorization of discrepancies as
minor discrepancies (mD), major discrepancies (MD) and very
major discrepancies (VMD) was performed as follows:
mD MD VMD
Broth microdilution S I I R S R
Disc diffusion I S R I R S
According to the recommendation in the ISO document,
results are acceptable if the overall categorical agreement (CA)
is ≥90% and the overall VMD and MD are ≤3%, respectively.
Discrepancies were resolved by retesting [5].
Results
A total of 5231 susceptibility tests performed with EUCAST
disc diffusion test and ISO broth microdilution were analysed.
Table 1 lists the organisms used and Table 2 lists the
antimicrobial agents investigated and the concentrations used.
The readings of quality control reference strains compared
with recommendations in EUCAST quality control tables are
shown in Table 3.
The overall CA for the disc diffusion test (5231 tests for 544
clinical isolates) was 97.3% (91.8–100%) (Table 4) and overall
mD, MD and VMD discrepancies were 110 (2.1%), 24 (0.5%)
and 7 (0.1%), respectively. All were in agreement with the ISO
acceptance criteria for accuracy assessment of susceptibility
test systems.
For Gram-positive organisms the overall CA (2346 tests)
was 98.7% and all organism groups had a CA higher than 96%
(Table 5a). For Gram-negative organisms the overall CA (2942
tests) was 96.2% with a CA higher than 95% for all organisms
except for P. aeruginosa and Morganella morganii, which both
had 91.8% (Table 5b). The low CA for P. aeruginosa was mainly
as a result of mD for aztreonam and meropenem and for
M. morganii mD for trimethoprim. The overall mD, MD and
VMD were below 3%. Seven VMD were observed, ﬁve in
Gram-positive (coagulase negative staphylococci (n = 2) and
S. aureus (n = 3), Table 5a) and two in Gram-negative organ-
TABLE 2. Antimicrobial agent evaluated for each species. Disc contents (lg) and range of MIC (mg/L) for the antimicrobials are
shown in the table
Antimicrobial disc (lg) Enterobacteriaceae Pseudomonas Staphylococci Streptococci Enterococci
Ampicillin (2) 2–8
Aztreonam (30) 0.5–16 0.5–16
Benzylpenicillin (1 unit) 0.06–2 0.06–2d
Cefepime (30) 0.5–16
Cefotaxime (5) 0.5–16
Cefoxitin (30) 2–8
Ceftazidime (10) 0.5–16 0.5–16
Cefuroxime (30) 1–16a
Ciproﬂoxacin (5) 0.03–2 0.03–2 0.5–2
Clindamycin (2) 0.06–1 0.06–1
Erythromycin (15) 0.06–4 0.06–4
Fusidic acid (10) 0.5–16
Gentamicin (10) 0.25–8 0.25–8 0.5–4
Gentamicin (30) 128–256
Imipenem (10) 0.25–16b 0.25–16 1–8
Linezolid (10) 1–4 0.5–4
Meropenem (10) 0.25–16 0.25–16
Moxiﬂoxacin (5) 0.12–2 0.12–1
Nitrofurantoin (100) 16–256
Piperacillin/Tazobactam (30–6) 0.5–32 0.5–32
Teicoplanin (30) 0.5–8
Tetracycline (30) 0.5–8 0.5–8
Tigecyclin (15) 0.12–4c
Tobramycin (10) 0.25–8 0.25–8
Trimethoprim (5) 1–4
Trim/Sulfa (1.25–23.75) 2–8 0.06–4
Vancomycin (5) 0.5–8
aBreakpoint only available for Escherichia coli, Proteus mirabilis and Klebsiella spp.
bBreakpoint excludes Proteus mirabilis and Morganella morganii.
cZone diameter breakpoints only valid for E. coli.
dBreakpoint only available for Streptococcus pyogenes.
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isms (P. aeruginosa; Table 5b). The 97 mD in the Gram-
negative organisms were distributed among all antimicrobial
agents and species (Table 5b). The main part of these
discrepancies, 35 mD (aztreonam, cefepime, ceftazidime and
piperacillin/tazobactam) occurred in ESBL-producing isolates
of E. coli and K. pneumonaie.
The CA was >95% for all except four antimicrobial
combinations. Three of the four were with Enterobacteriaceae
aztreonam (CA 91.6%), cefotaxime (93.6%) and ceftazidime
(92.6%) and one with Enterococci and ampicillin (93.9%).
Fig. 1(a–c) shows the relationship between MIC and zone
diameter for Enterobacteriaceae and aztreonam (Fig. 1a; CA
91.6%, which was the lowest of all), ciproﬂoxacin (Fig. 1b; CA
98%, which was representative of many antimicrobials) and
cefuroxime (Fig. 1c; with a CA >99%, which it shared with
imipenem, meropenem and tigecycline).
Isolates with known and/or genetically deﬁned resistance
mechanisms such as MRSA, vancomycin-resistant enterococci,
ESBL-producing Enterobacteriaceae and high level aminogly-
coside resistance in enterococci were all correctly categorized
by both disc diffusion and broth microdilution. For the
inducible clindamycin resistance all strains were detected by
the D-phenomenon in the disc diffusion test.
Discussion
The main objectives of EUCAST are to harmonize antimicro-
bial breakpoints in Europe, determine clinical breakpoints for
new antimicrobials and develop methods for susceptibility
testing. The EUCAST disc diffusion test is currently being
implemented in many European countries and some countries
outside Europe. We used a collection of relevant clinical
isolates and antimicrobial agents to validate EUCAST clinical
zone diameter breakpoints from the EUCAST breakpoint table
version 2.0 against MICs obtained with the reference broth
microdilution method described by ISO.
The disc diffusion test results showed a high correlation to
MIC results with a ﬁnal overall CA at 97.3% and a CA higher
than 95% for 13 of 15 evaluated species. Gram-positive
organisms had a slightly higher CA (98.7%) than the
Gram-negative organisms (96.3%). The correlation between
MICs and zone diameter breakpoints was generally excellent
and the discrepancies for P. aeruginosa and M. morganii (versus
aztreonam and meropenem and trimethoprim, respectively)
were caused by MIC breakpoints dividing the wild-type
distributions and this is known to invite errors [7,8]. Some
isolates categorized as resistant by MIC were erroneously
categorized as intermediate by the disc diffusion test. The
EUCAST breakpoints are valid for all genera of Enterobacte-
riaceae but were mainly determined on data for E. coli and
K. pneumoniae. To avoid the disc diffusion breakpoints dividing
the wild-type distributions of Proteus mirabilis and M. morganii,
the MIC breakpoints would have to be adjusted. We suggest
that EUCAST look into this issue because with MIC break-
points cutting into wild-type MIC distributions reproducibility
is poor [7–9]. This can be further exempliﬁed by the low CA of
91.8% for Enterobacteriaceae versus aztreonam. In Fig. 1(a)
TABLE 3. Susceptibility test results with quality control reference strains
Reference strain
MIC (mg/L) Inhibition zone diameter (mm)
No. of tests In range Out of range No. of tests In rangea Out of range Failed test
Staphylococcus aureus ATCC 29213 45 45 0 36 35 (21) 1 Disc diffusion–Moxiﬂoxacin high
Enterococcus faecalis ATCC 29212 18 18 0 6 6 (5) 0
Streptococcus pneumoniae ATCC 49619 4 4 0 8 8 (5) 0
Escherichia coli ATCC 25922 84 83 1 42 42 (36) 0 MIC-Gentamicin high
Pseudomonas aeruginosa ATCC 27853 24 23 1 7 7 (4) 0 MIC-Ciproﬂoxacin low
Staphylococcus aureus ATCC 43300b 1 1 0 – – –
Klebsiella pneumoniae ATCC 700603c 4 4 0 – – –
Total (n) 180 178 2 99 98 (71) 1
aIn parenthesis is the number of readings which were within +/1 mm of the target.
bOnly used for susceptibility testing of methicillin-resistant Staphylococcus aureus isolates. Quality control values only for cefoxitin MIC >4 mg/L from CLSI, M100.
cOnly used for susceptibility testing of extended spectrum b-lactamase producing Enterobacteriaceae isolates. Quality control values only for cefotaxime MIC ≥2 mg/L and
ceftazidime MIC ≥2 mg/L from CLSI, M100-S23, 2013. No quality control values for disc diffusion.
TABLE 4. Category agreement (CA) between the EUCAST
disc diffusion test and the broth microdilution method and for
Gram-negative and Gram-positive organisms
Species
No. of
isolates
No. of
tests CA CA%
Staphylococcus aureus 94 940 933 99.3
Coagulase-negative
staphylococci
28 280 271 96.8
Staphylococcus lugdunensis 9 90 90 100
Enterococcus faecalis 41 287 286 99.7
Enterococcus faecium 57 342 334 97.7
Streptococcus pneumoniae 35 140 135 96.4
Streptococcus pyogenes 42 210 210 100
Escherichia coli 87 1218 1176 96.6
Klebsiella pneumoniae 50 650 629 96.8
Klebsiella oxytoca 12 156 149 95.5
Morganella morganii 10 110 101 91.8
Proteus mirabilis 22 264 263 99.6
Enterobacter cloacae 13 156 151 96.8
Enterobacter aerogenes 9 108 105 97.2
Pseudomonas aeruginosa 35 280 257 91.8
Total 544 5231 5090 97.3
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each isolate in the zone diameter histogram is shown in a
colour representing its MIC value [9]. There is a good
correlation between MIC and zone diameters but the results
suggest that the zone diameter breakpoints need to be
adjusted to avoid bisecting the wild-type population. Our data
support breakpoints of S ≥ 24 mm and R < 18 mm rather
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FIG. 1. EUCAST disc diffusion inhibition zone diameter histograms displaying the zone diameter (bars) and broth microdilution MIC value (colour
code) for each isolate. (a) Enterobacteriaceae (see Table 1 for list of species) versus aztreonam (categorical agreement (CA) 91.6%). The zone
diameter breakpoints for Enterobacteriaceae are S ≥27 and R <24 mm (corresponding to clinical breakpoints of S ≤1 mg/L, R >4 mg/L). (b)
Enterobacteriaceae (see Table 1 for list of species) versus ciproﬂoxacin (CA 97.9%). The zone diameter breakpoints for Enterobacteriaceae are
S ≥22 and R <19 mm (corresponding to clinical breakpoints of S ≤0.5 mg/L, R >1 mg/L). (c) Enterobacteriaceae (see Table 1 for list of species)
versus cefuroxime (CA 99.4%). The zone diameter breakpoints for Enterobacteriaceae are S ≥18 and R <18 mm (corresponding to clinical
breakpoints of S ≤8 mg/L, R >8 mg/L).
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than the current S ≥ 27 mm and R < 24 mm. This would
resolve 15 of 16 mD and one MD would change to an mD,
resulting in an increase in the CA from 91.8% to 99.2% (Fig 1).
This also illustrates an important point pertaining to the use of
calculating CA and discrepancies (mD, MD and VMD). At least
four separate variables inﬂuence the results of the calculations
of CA: (i) the number of species and which species were
included, (ii) the proportion of isolates with and without
resistance to the agent (and the proportions of low- and
high-level resistance), (iii) whether clinical breakpoints were
adjusted to avoid dividing wild-type MIC distributions of
important target organisms and, most importantly, (iv)
whether the clinical breakpoints include intermediate catego-
ries and the width of these. The collection of isolates used to
establish zone diameter breakpoints can easily be put together
to obscure or disclose problems with CA. The latter is
achieved by including many species, which may have different
wild-type MIC distributions, and/or many isolates near the
breakpoints to facilitate a favourable outcome. This former is
achieved by avoiding isolates with MICs near breakpoints and
allowing one, well-controlled species to dominate the collec-
tion of species tested. If clinical breakpoints were set to avoid
dividing wild-type MIC distributions of target organisms, it is
easier to achieve good CA. If on the other hand the clinical
MIC-breakpoints divide the wild-type of an important organ-
ism, VMD and MD can be transformed into MD and mD,
respectively, by increasing the width of the intermediate
category. However, in the EUCAST system for setting
breakpoints a major function of the intermediate category is
not to act as a methodological buffer to avoid errors but to
signal that dosing should be at the highest level. This leaves
‘pharmacokinetic/pharmacodynamic room’ for an intermediate
category of only one or two dilution steps. A recent paper
criticized the width, or rather lack of width, of EUCAST
intermediate categories and suggested that CLSI intermediate
categories were more appropriate because they generated
fewer VMD and MD [10]. Statistically this may be correct but
from a biological and therapeutic standpoint a breakpoint
committee setting clinical MIC breakpoints should make an
effort to categorize isolates correctly into susceptible, inter-
mediate and resistant and simultaneously to avoid dividing
wild-type MIC distributions because this is the most important
reason for signiﬁcant problems with mD, MD and VMD. Use of
the intermediate category simply to avoid MD and VMD also
restricts the use of potentially useful agents. As the susceptible
category relates to ‘common dosing regimens’ (which in
EUCAST are clearly deﬁned) and the resistant breakpoint is
deﬁned by the highest possible dose, the intermediate category
must relate to a dose that is above normal but no higher than
the highest permitted dose. With the exception of many
b-lactam agents, this leaves room for only narrow intermedi-
ate categories.
There were two VMD for S. aureus and benzylpenicillin. The
isolates were classiﬁed as R by the reference method and S by
the disc diffusion method. However, disc diffusion is consid-
ered more reliable than MIC determination for the detection
of b-lactamase in S. aureus [11]. The isolates were retested for
both disc diffusion and MIC with E-test. Both zone diameters
were 29 mm, zone edges were fuzzy and the MIC results were
0.06 mg/L, which indicates that susceptible would be the
correct categorization. According to EUCAST instructions,
the b-lactamase production is detected by measuring the zone
diameter and inspecting the zone for the presence of sharp
(b-lactamase positive) or fuzzy (b-lactamase negative) zone
edge [6]. Those S. aureus isolates that have a sharp zone edge
should be reported R for benzylpenicillin and as b-lactamase
producers irrespective of inhibition zone diameter [11].
In summary, susceptibility testing performed with EUCAST
disc diffusion methodology and zone diameter breakpoints
exhibited a high degree of categorical agreement with
susceptibility testing performed with reference MIC determi-
nation. For all species and antimicrobials, the standards
determined by ISO for validating susceptibility testing were
attained. The few recorded problems could be referred
problems with the breakpoints dividing distributions of
wild-type isolates.
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